featured-image

Dr. Ronny Gal, Novartis's Chief Strategy and Growth Officer: Our aim is that half our innovative products should come from outside the company. At the beginning of 2023, Dr.

Ronny (Aharon) Gal, one of the best known and longest-serving analysts in the biopharmaceuticals, surprised the market when he announced a change of career. Gal, who had worked as a senior analyst at investment bank Sanford Bernstein, crossed the lines and joined pharmaceuticals company Novartis as its Chief Strategy and Growth Officer and a member of its executive committee. The appointment was part of the strategy of Novartis CEO Vasant Narasimhan, who declared at the time that he didn't want to bring the largest number of drugs to the market, but the most innovative drugs, with the greatest impact on patients' lives.



This week, as part of that strategy, Novartis held a conference under the slogan "Ignite Your Curiosity", in collaboration with venture capital firm aMoon and Startup Nation Central. For several years now, the company has held such conferences, at which it presents its vision and the areas and ways in which it seeks to collaborate with Israeli biopharmaceutical companies and with academic institutions in Israel. "I wanted the excitement of Wall Street" In conversation with Dr.

Yaron Daniely, a general partner at aMoon, Gal indicated the directions on which the company currently wishes to focus, but before that he talked about how he arrived at his present position. "The CEO, Narasimhan, wo.

Back to Health Page